Please assess the completion status of the following clinical trial:

Trial Title: Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Each participant must be at least 18 years of age~* Male, or a female who is not of child-bearing potential or who is non-pregnant, non-lactating, and is using a medically accepted method of contraception~* Each participant must have a current diagnosis of Bipolar I Disorder, current episode manic or mixed~* Each participant must be confirmed to be experiencing an acute manic or mixed bipolar 1 episode~* Each participant must have discontinued the use of all prohibited psychotropic medications~Exclusion Criteria:~* A participant must not have a primary Axis I disorder other than Bipolar 1 Disorder (i.e., an Axis 1 disorder other than Bipolar 1 Disorder that is primarily responsible for current symptoms and functional impairment)~* A participant must not currently (within the past 6 months) meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR™) criteria for substance abuse or dependence (excluding nicotine)~* A participant must not be at imminent risk of self-harm or harm to others, in the investigator's opinion based on clinical interview and responses provided on the Columbia Suicide Severity Rating Scale (CSSRS).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine 5 mg BID (Type: EXPERIMENTAL): Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
- Asenapine 10 mg BID (Type: EXPERIMENTAL): Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
- Placebo BID (Type: PLACEBO_COMPARATOR): Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).